Obesity is not only associated with the development of diabetes and hypertension, but is also a known risk factor for chronic kidney disease (CKD) and is a risk factor for progressive renal function loss. Abdominal obesity is especially related to incident CKD and mortality. The decline in fat mass over time has also been related to mortality in this population. In patients on peritoneal dialysis, intra-abdominal fat accumulation has been related to cardiovascular morbidity and mortality. The body mass index is a simple method to estimate fat mass in dialysis patients. Maximum abdominal circumference, triceps and subscapular skinfolds, and arm circumference have been proposed as alternative methods in assessing subcutaneous adipose tissue to overcome the altered hydration status associated with dialysis. Waist-to-hip ratio, waist-to-height ratio and the conicity index are used to estimate abdominal fat deposits. Dual-energy X-ray absorptiometry, bioelectrical impedance analysis, computed tomography and magnetic resonance imaging are more precise and reliable methods to estimate body composition in dialysis patients. Adipose tissue is the source of a novel group of hormonally active substances known as adipokines. Patients with CKD exhibit an increase in serum concentration of most of these substances. Besides, the kidney plays an important role in the regulation of adipokines, and altered renal handling of these substances might contribute to an increase in the uraemia-associated increased risk of cardiovascular disease and mortality. In particular, pro-inflammatory adipokines, such as leptin, tumour necrosis factor-alpha and inteleukin-6, have been associated with an increased risk of mortality, whereas the link between adiponectin, an antiatherogenic adipokine, and survival is controversial in patients with CKD.
Introduction
Adipose tissue consists of fat cells (adipocytes) and a component stromal/vascular in which the preadipocytes are found. Normally, the cellular content of adipose tissue is ∼50% adipocytes, the remaining 50% being the vascular stroma, fibroblasts, endothelial cells, macrophages and preadipocytes. There are two types of adipose tissue and, therefore, two different types of fat cells: (i) white adipose tissue, which is the most abundant in adult human body and therefore the largest energy reservoir, and (ii) brown adipose tissue, which is responsible for thermogenesis. Adipose tissue is more than a passive store of triglycerides since numerous cytokines, commonly known as adipokines, are released by fat tissue. Normally, 80% of adipose tissue is located in the subcutaneous tissue, while visceral adipose tissue (VAT) is <20%. The VAT is composed of adipocytes of smaller size and less storage capacity, which are more vascular, with increased sympathetic innervation and a large number of β3-adrenergic receptors, which facilitates a higher metabolic activity [1] .
Different fat depots (abdominal visceral, abdominal subcutaneous, total subcutaneous and total body fat) are not equivalent from a functional point of view. VAT mass has a higher degree of metabolic activity compared with subcutaneous peripheral adipose tissue (SAT). In fact, VAT is considered an important and independent predictor of risk for coronary heart disease as other known risk factors such as insulin, insulin resistance, hypertension, impaired glucose tolerance, diabetes and dyslipidaemia [2] [3] [4] [5] . VAT correlates directly with intrahepatic triglyceride content, a better marker of the metabolic derangements associated with obesity [6] . Other fat depots such as abdominal subcutaneous, intra-organ and peri-organ fat may have metabolic activity between that of peripheral subcutaneous fat and VAT. Different factors such as capacity of preadipocyte differentiation, adipocyte apoptosis, lipolysis, lipogenesis, adipocyte receptors, and cytokines and adipokines secretion are also different among several types of fat depots [1] .
When fat cells enlarge, for unknown reasons, they secrete factors that attract inflammatory cells or macrophages, which in turn release toxic factors, such as interleukins, responsible for causing damage to the liver and other organs, such as arteries, and promote insulin resistance leading to type 2 diabetes [7] [8] [9] .
Recent studies have reported that abdominal fat plays an important role in metabolic syndrome, because it is predictive of sensitivity to insulin and is closely related to the development of type 2 diabetes, heart disease and cardiovascular mortality independent of total body fat [10, 11] . Similarly, it has been reported that obesity adversely affects renal function and may be associated with morbidity and mortality in patients with chronic kidney disease (CKD). The objectives of this review are: (i) to analyse the relationship between the quantity and distribution of adipose tissue and different renal diseases, and (ii) to assess the role of adipokines in patients with kidney disease.
Adipose tissue and renal disease
Obesity-associated kidney injury. Obesity may be associated with different renal lesions such as micro-and macroalbuminuria, nephrotic-range proteinuria, glomerulomegaly with or without focal or segmental glomerulosclerosis, diabetic nephropathy, urolithiasis, and renal carcinoma [12] [13] [14] [15] [16] .
Both percentage of total body fat and body fat distribution are related to albumin excretion rate (AER) in humans. Obesity is significantly related to increased AER, and in subjects who have the same percentage of total body fat, those with central fat distribution are at increased risk for AER [17] . Several factors associated with obesity may contribute to proteinuria, mainly glomerular hyperfiltration, and mesangial cell hypertrophy and matrix production. Among them are high protein and salt intake, hyperinsulinaemia, hyperlipidaemia, increased sodium tubular reabsorption and synthesis of several adipose tissue-derived substances such as pro-inflammatory adipokines (leptin), plasminogen activator inhibitor-1, angiotensin II, and growth factors [transforming growth factor-β1 (TGF-β1)]. Although lifestyle modification (salt restriction, hypocaloric diet and regular aerobic exercise) and angiotensinconverting enzyme inhibitors have shown beneficial effects on obesity-associated proteinuria, only weight loss in early stages of the disease remains the most effective measure to control definitively these renal changes [12, 15] .
The prevalence of diabetes and hypertension increases in parallel with obesity, and these are well-known risk factors for kidney disease. The kidney of an obese subject is more vulnerable to damage from hypertension and diabetes. Furthermore, the prognosis of the diseases that initially affect only the kidney is less favourable when they appear in obese people [14] .
A high body mass index (BMI) is associated with increased risk of symptomatic urolithiasis and recurrent stone formation [18] [19] [20] [21] [22] [23] . The main pathogenic mechanisms by which obesity increases the risk of urolithiasis are the increased urinary excretion of lithogenic substances such as calcium, oxalate and uric acid secondary to a high food intake and the lower urine pH caused by deficient ammonia production probably related to insulin resistance [21, 24] . Although weight control may be considered one of the preventive modalities against recurrent stone formation, especially in first-time stone formers [22] , some types of hypocaloric diets, especially low-carbohydrate diets, increase the risk of both calcium and uric acid stones. Moreover, bariatric surgery may cause hyperoxaluria with associated stone formation and even oxalate nephropathy [21, 22] .
Recent studies have established that obesity increases the likelihood of developing several cancers; among them is renal cell carcinoma [25] [26] [27] . Several pathogenic mechanisms such as lipid peroxidation [28, 29] , hormonal changes (high leptin, insulin, oestrogen and low adiponectin) [28, 30, 31] and immune malfunction [28] associated with high BMI have been implicated. Low serum total and high-molecular-weight adiponectin levels have also been reported in patients with metastatic renal cell carcinoma, suggesting that adiponectin might be a molecular link between obesity and the progression of renal cell carcinoma [32] .
Obesity and chronic kidney disease. A positive association between high BMI and risk for CKD has been reported [33, 34] . A high BMI is associated with many complications such as hypertension, dyslipidaemia, hyperglycaemia, insulin resistance, and glomerular hyperperfusion and hyperfiltration resulting in renal injury with proteinuria 'obesity-related glomerulopathy' [35] [36] [37] . As occurs in the general population, obesity, a traditional risk factor for atherosclerosis, is associated with inflammation also in CKD patients [38] . BMI has been considered as a common, strong and potentially modifiable independent risk factor for CKD [33] . In a large study performed in 320 252 adult volunteers, the adjusted relative risk for end-stage renal disease (ESRD) was 3.6 (95% CI, 3.05-4.18) for those with class I obesity (BMI, 30.0-34.9 kg/m 2 ), 6.1 (95% CI, 5.0-7.5) for those with class II obesity (BMI, 35.0-39.9 kg/m 2 ) and 7.1 (95% CI, 5.4-9.30) for those with morbid obesity (BMI ≥40 kg/m 2 ) compared with persons who had normal weight (BMI, 18.5-24.9 kg/m 2 ). This finding persisted even after additional adjustments for baseline blood pressure level and presence or absence of diabetes mellitus [33] . These results have been recently confirmed by the same group which evaluated risk factors for ESRD in 177 570 individuals in a 25-year follow-up study. In this study, excess weight and proteinuria were the two most potent risk factors for ESRD [33] . Hormonal changes, low-grade inflammation, oxidative stress and endothelial dysfunction are the main possible pathogenic mechanisms of renal damage in obesity [34, [39] [40] [41] . Although the association between high BMI and risk for CKD has been reported by others [34] , not all studies have been able to demonstrate a significant association after adjusting for known cardiovascular disease risk factors, considering that such association might be mediated by cardiovascular risk factors [34] . Lastly, other studies have shown that abdominal adiposity measured by waist-to-hip ratio (WHR) [42] Obesity is the aetiology of CKD of 15% in men and 11% in women. This excess risk for CKD among obese people appears mainly to be driven by a high prevalence of hypertension and/or type 2 diabetes. Obesity (BMI ≥30) patients at any age is 3-4 times more likely to develop CKD. The link between obesity and CKD is strongest for diabetes-related kidney disease [46] .
Elevated blood pressure has been reported to be related to an increased VAT [5] . In rodent models, metabolic syndrome is associated with perivascular adipose inflammation and oxidative stress, hypertrophic resistance artery remodelling, and endothelial dysfunction secondary to decreased nitric oxide [47] . VAT produces adipokines that contribute to the pathophysiologic renal haemodynamic and structural changes leading to obesity-related nephropathy [48] . It has been suggested that VAT may represent an important clinical target in the management of elevated blood pressure [5] .
Low serum high-density lipoprotein (HDL) cholesterol level is common in CKD patients. Although high BMI values have been associated with low HDL cholesterol levels across a spectrum of estimated glomerular filtration rate (eGFR), the magnitude of this association diminishes at lower eGFR, suggesting that other factors might contribute to low HDL levels in advanced CKD patients [49] .
Adipose tissue, and morbidity and mortality in dialysis patients
Obesity is associated with several metabolic and cardiovascular complications in the general population, including hypertension, type 2 diabetes mellitus, dyslipidaemia, obstructive sleep apnoea and sleep-disordered breathing, certain cancers, and major cardiovascular (CV) diseases (heart failure, coronary heart disease, sudden cardiac death and atrial fibrillation) [50, 51] . Also in CKD, there is a wellknown relationship between body fat depots and cardiovascular morbidity and mortality [52, 54] .
Adipose tissue and haemodialysis. A low body fat mass estimated by BMI together with other markers of protein-energy wasting (PEW) such as hypoalbuminaemia, low serum cholesterol levels and reduced dietary protein intake are important predictors of mortality in CKD populations not only in pre-dialysis stages but also in haemodialysis (HD) patients [52] [53] [54] . This fact is important because, although body fat mass increases significantly in the first year of maintenance HD, especially in patients with poor nutritional status [55], more than one-half of the HD patients older than 65 years are usually malnourished [56] .
On the contrary, whereas BMI predicts mortality in the general population, some studies have reported that high body fat mass estimated by BMI (>25 kg/m 2 ) is associated with a reduced all-cause and cardiovascular (CV) mortality in HD patients ('obesity paradox'), i.e. a high BMI is incrementally associated with better survival [53,57-62]. It would indicate that fat mass rather than lean mass plays a protective role against mortality in HD patients [61] . Several causes have been proposed for this 'obesity paradox' in these patients. Among them are genetic, biochemical (adipocytokines), haemodynamic and neurohormonal factors [59] . However, we should be cautious in interpreting the 'obesity paradox' as a true fact, due to the many confounders that are likely to affect the outcome in large epidemiological studies underpinning this hypothesis, and the conflicting data from Europe [63,64] and US HD patients [65] . Pros and cons on whether epidemiological data derived from the healthy general population may or may not be applicable to ESRD have been recently analysed [66, 67] . Some authors consider, on one hand, that adequate energy stores are necessary to survive semi-starvation associated with dialysis and, on the other, that some established risk factors related to obesity might be less relevant in dialysis patients [66] . However, other authors think that observed discrepancies between the general population and dialysis patients might be related to several factors such as observation time and age between the general population and dialysis patients, as well as differences in ethnicity and nutritional intake [67] .
Fat mass change over time has been considered as a risk factor for mortality in HD patients and has been proposed as a useful parameter for measurement of nutritional status in these patients [54, 68] . In a study performed in 190 HD female patients with a similar initial body fat mass and followed up for 5 years, the decrease in annual fat mass estimated by dual-energy X-ray absorptiometry (DXA) was a significant predictor of all-cause mortality [68] .
Although VAT has been related to lipid and carbohydrate metabolism and atherosclerosis in HD patients [69], a close relationship between subcutaneous fat accumulation (SFA) and insulin resistance or atherosclerosis in these patients has also been recently reported, suggesting that SFA plays important roles related to carbohydrate or lipid metabolism in HD patients [70] . Lastly, abdominal fat deposition in HD patients has been reported to be linked to both inflammation and PEW, resulting in an increased mortality risk [71] .
Adipose tissue and peritoneal dialysis. Unlike HD, peritoneal dialysis (PD) patients tend to gain weight after starting renal replacement therapy, probably as a result of continuous glucose absorption [72, 73] . Administration of glucose-containing peritoneal dialysis solution increases lipogenesis in the liver [74] . This weight gain is mainly due to the intra-abdominal fat accumulation [73] . This fact 2068 Nephrol Dial Transplant (2010): Editorial Reviews has been proposed as one of the mechanisms by which the risk to develop cardiovascular morbidity and mortality in PD patients could be increased [73] . However, the relationship between overweight and/or obesity and mortality in PD patients has not been clearly established [75] [76] [77] . It has been recently reported that the level of VAT is related to parameters that measure arterial stiffness and endothelial dysfunction in PD patients. In fact, VAT estimated by multiple-frequency bioelectrical impedance analysis (BIA) was associated with an increase in pulse-wave velocity and a reduction in brachial artery flow-mediated dilation [78] . These findings have led some authors to consider the visceral fat as a risk factor for cardiovascular disease in these patients.
Quantification of adipose tissue in renal disease
In CKD patients, adipose tissue can be estimated by means of anthropometric and body composition assessment (Table 1) . Dialysis per se can present special problems for anthropometry, including decreased functional status and increased co-morbidity that challenge nutrition assessment methodology [79] . Due to the altered hydration status associated with dialysis, it is recommended that both anthropometric and body composition analysis measurements be performed after dialysis. In comparison with healthy persons of the same ages, HD patients usually are, on average, lighter with less adipose and muscle tissue [79] [80] [81] [82] . Diabetes is associated with increased body fat content in dialysis patients [83, 84] . On the other hand, time on dialysis is also negatively related to body fat, showing greater loss of fat mass in patients with longer duration of dialysis [79, 82] . HEMO Study data provide a clinical reference for the use of anthropometric parameters in assessing the nutritional status in HD patients [82] . Although BMI or Quetelet index, defined as the individual's body weight divided by the square of his or her height, does not actually measure the percentage of body fat, it provides a good correlation with total body fat. BMI is an appropriate, simple and cheap measurement, and low BMI value is closely associated with mortality in HD patients [85] . For that reason, it is generally used as a vague means of estimating adiposity and is being widely used for identifying individuals with underweight, overweight or obesity. However, due to the fact that BMI is unable to distinguish muscle and fat compartments, some authors have proposed that maximum abdominal circumference (MAC), in addition to height and weight, be included in studies relating body composition to outcomes in HD patients because this measure provides a better estimate of the metabolically active VAT pool in these patients [86, 87] . In CKD patients, WC has shown a strong association with VAT and has been associated with cardiovascular disease risk factors similar to those observed for VAT, particularly in men, suggesting that this anthropometric parameter might be a simple, reliable and inexpensive tool to be used in epidemiological studies in CKD patients [87] . Triceps (TSF) and subscapular (SSF) skinfolds are the best anthropometric parameters for measuring subcutaneous fat thickness on the limbs and trunk, respectively. TSF has a moderate accuracy and utility and a very high reliability in assessing SAT, whereas the accuracy, utility and reliability of SSF are only moderate [79] . Arm circumference (AC) is other anthropometric parameter that can also be useful in estimating the SAT in patients on dialysis [79] .
Several parameters are being used for estimating abdominal fat deposition such as WHR, waist/height ratio, conicity index and several predictive equations by means of variables such as age, sex, and waist and hip circumferences [71, [88] [89] [90] [91] .
Among the methods most commonly used to analyse body fat in dialysis patients through body composition analysis are DXA and BIA. DXA has been used for body composition analysis in dialysis patients and has shown an excellent precision in the evaluation of body composition, fat content and nutritional evaluation [92] . BIA calculates an estimate of total body water (TBW) by means of the analysis of the opposition to the flow of an electric current through body tissues. TBW is then used to estimate fat-free body mass and, by difference with body weight, body fat. For non-obese clinically stable non-dialysed CKD patients, anthropometric and BIA can be applied equally well for assessing body fat; however, a weak correlation has been reported for overweight/obese patients [93] . BIA equations usually estimate decreased fat mass index in ESRD patients when comparing with healthy population [94] . 
Better mortality predictor than TNF-α in CKD and HD Correlates positively with human obesity and insulin resistance Predictive of type 2 diabetes Associated with the appearance of coronary heart disease events, congestive heart failure events and stroke events Resistin Regulation of metabolism Elevated serum levels Inhibition of adipogenesis and inflammation Similar levels in both HD and PD Associated to heart disease in dialysis?
EPO, epoetin; ESRD, end-stage renal disease; CKD, chronic kidney disease; CV, cardiovascular; IL-6, interleukin-6; BMI, body mass index; TNF-α, tumour necrosis factor-alpha; HD, haemodialysis; PD, peritoneal dialysis.
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At present, abdominal fat distribution (VAT and SAT) can also be quantified by computed tomography (CT) scan [70] and magnetic resonance imaging (MRI) [96] at the level of the umbilicus in HD patients for estimating cardiovascular risk. However, these techniques are expensive and not feasible in clinical practice.
Adipokines in chronic renal disease
Adipose tissue is currently considered as a hormonally active system in the control of metabolism and not only as a store of excess energy. It is the source of a number of pro-inflammatory adipokines, such as leptin, resistin, tumour necrosis factoralpha (TNF-α) and IL-6, as well as one anti-inflammatory adipokine, adiponectin. Previous studies have found that ESRD patients have markedly increased circulating levels of pro-inflammatory and anti-inflammatory adipokines [97, 98] . It might be due to an increase in their systemic production, a decreased renal degradation and an increased infiltration of adipose tissue by immunocompetent cells (CD68) with an increased expression of some, but not all, pro-inflammatory cytokines such as TNF-α [97] [98] [99] . In this setting, ESRD could lead to retention of pro-inflammatory adipokines, thus generating adipokine imbalance, and could lead to contribution to wasting, atherosclerosis and insulin resistance [57, 100, 101] . Adipokines influence systemic inflammation, endothelial health and appetite in CKD patients, and have been considered as morbi-mortality risk factors in both HD [102] [103] [104] and PD [72, 105] patients (Table 2) .
Leptin. The ob gene product leptin, a 16-kDa protein containing 167 amino acids, is secreted by adipocyte and reflects the content of body fat. This adipokine is related to the control of food intake, appetite and energy expenditure. Leptin has also been considered as a pro-inflammatory adipokine. It has been reported that an association between leptin and metabolic risk factors such as BMI, WC and high-sensitivity C-reactive protein (hsCRP) revealed a close link between metabolic syndrome, obesity and inflammation [106] . Some studies performed in type 2 diabetic patients have reported that leptin is regulated or affected by multiple factors including renal function [107] .
Serum leptin concentrations are markedly elevated in CKD [108] [109] [110] [111] [112] [113] . The kidney is not only a site of leptin metabolism but also a target organ for leptin action. In fact, leptin stimulates cellular proliferation, TGF-β1 synthesis and type IV collagen production in glomerular endothelial cells. Conversely, in mesangial cells, leptin upregulates synthesis of the TGF-β type II receptor, but not TGF-β1, and stimulates glucose transport and type I collagen production through signal transduction pathways involving phosphatidylinositol-3-kinase. These data suggest that leptin triggers a paracrine interaction in which glomerular endothelial cells secrete TGF-β to which sensitized mesangial cells may respond [114] .
Recent studies have shown that adipokines may influence bone turnover [57]. Leptin is a major regulator of bone remodelling through a hypothalamic relay and by using two neural mediators: the sympathetic tone, and cocaine-and amphetamine-regulated transcript (CART), a brain-located peptide, both acting on the osteoblast [115, 116] . This regulation of bone remodelling by leptin implies that bone may exert a feedback control of energy homeostasis [117] . On the other hand, leptin stimulates human erythroid development in vitro [118] , and body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD [119] . A reciprocal relationship between bone marrow adiposity and bone loss has been suggested [117, 120] .
Although leptin acts negatively on appetite, most studies have failed to demonstrate any relationship between leptin and anorexia in dialysis patients [121] . As occurs in healthy individuals, leptin correlates positively with body fat in CKD patients [110, 112] . This hormone serves as a useful clinical marker of body fat content in both HD [109] and PD [108] patients. Moreover, leptin correlates strongly to changes in body fat during 12 months after starting PD [112] . On the other hand, leptin has also been associated with inflammation in CKD [122] . Uraemic patients with ongoing signs of inflammation (hsCRP levels) show higher serum leptin levels than patients with normal CRP [112] .
An inverse association between leptin, bone mass and PTH in dialysis patients has been reported, suggesting that leptin may be implicated in low bone turnover in these patients [123] . Increases in serum leptin during PD are associated with inflammation and a decrease in lean body mass. Leptin has also been associated with atherogenic lipid profile and insulin resistance in CKD patients. In fact, leptin independently predicted total cholesterol and triglycerides [111] , and correlated with plasma insulin concentrations independent of body fat content in CKD [124] . All these observations may contribute to the elevated cardiovascular risk that has been linked to hyperleptinaemia in CKD patients. On the other hand, a prospective long-term study in patients with CKD stage 5 on HD showed that reduced serum leptin concentration is also an independent risk factor for mortality in these patients [125] , confirming that underweight is a mortality risk factor in this population.
Adiponectin. Adiponectin, a 26.4-kDa protein containing 244 amino acids specifically expressed in human adipose cells, is the most abundant adipokine in human plasma. This adipocyte-derived hormone increases insulin sensitivity and has anti-inflammatory and anti-atherogenic properties. Adiponectin has been shown to correlate negatively with glucose, insulin, triglyceride levels and BMI, and positively with high-density lipoprotein cholesterol levels and insulin-stimulated glucose disposal [126, 127] .
Serum adiponectin is invariably elevated in CKD [102] [103] [104] [105] 110, [128] [129] [130] [131] . In type 2 diabetic nephropathy, serum adiponectin levels are strongly and positively associated with fasting insulin levels and insulin resistance [132] . In uraemic patients, this adipokine is also inversely associated with metabolic risk factors, such as body mass index, blood glucose, insulinaemia, and serum triglyceride and HDL cholesterol levels [128] .
Adiponectin also plays a role in the regulation of bone turnover [133] . In a recent study, adiponectin was an independent predictor of bone mineral density in postNephrol Dial Transplant (2010): Editorial Reviews 2071 menopausal women, and positively correlated with bone turnover biochemical markers, suggesting that adiponectin may exert a negative effect on bone mass by promoting excessive bone resorption associated with bone loss [134] . This finding might be of interest when treating CKD patients. Adiponectin has been inversely associated with the development of cardiovascular events in patients undergoing HD [102, 103] . Moreover, some studies have shown a relation between low adiponectin and mortality in HD patients [104] . Similarly, the cumulative survival without new cardiovascular events has been reported to be better in PD patients with higher adiponectin levels than in those with lower adiponectin levels [135] . More recently, it has been reported that high stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients [105] . These data suggest that adiponectin might act as a protective factor against atherosclerosis in CKD patients. However, the contrary has been reported in other HD populations, such as diabetic HD patients, in which high adiponectin levels at baseline and increasing longitudinal levels of adiponectin during follow-up were associated higher risks of adverse cardiovascular outcomes and death [136] .
Visfatin. Visfatin is an adipocytokine highly enriched in the visceral fat of both humans and mice, and whose expression and plasma levels increase during the development of obesity. It was isolated and identified recently by Fukuhara et al. [137] . Visfatin corresponds to a protein identified previously as pre-B-cell colony-enhancing factor (PBEF), a 52-kDa cytokine expressed in lymphocytes [138] . Apart from adipocytes, macrophages, dendritic cells and colonic epithelial cells might be additional sources of visfatin. In their initial study, Fukuhara et al. [137] found that visfatin exerted insulin-mimetic actions in cultured cells and lowered plasma glucose levels in mice. Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild-type littermates. Surprisingly, these authors also found that visfatin was bound to an activated insulin receptor. Subsequent studies of visfatin in humans have generally not confirmed this initial study, which was, in part, retracted [139] .
Visfatin is nowadays considered as a new pro-inflammatory cytokine with functions related to energetic metabolism, immunity and insulin action. Inside the cells, visfatin acts as a nicotinamide phosphoribosyltransferase involved in the biosynthesis of NAD + , thus exercising influence on cell energetic metabolism and the activity of NAD + /NADHdependent enzymes [140] . Outside the cells, visfatin acts as an inductor of both pro-and anti-inflammatory cytokine expressions [141] . In CD14(+) monocytes, visfatin induces the production of IL-1β, TNF-α and especially IL-6. Moreover, it increases the surface expression of co-stimulatory molecules CD54, CD40 and CD80. Visfatin-induced effects involve p38 as well as MEK1 pathways as determined by inhibition with MAPK inhibitors, and an activation of NF-κB has also been observed [141] .
Axelsson et al. [142] studied 189 patients with CKD and found that visfatin levels were greater in patients with CKD stage 5 than in those with CKD stages 3-4 or healthy controls. However, there were no significant differences between patients with and without diabetes. Visfatin level correlated with IL-6, hsCRP and soluble vascular cell adhesion molecule-1 (sVCAM-1), but not total or truncal fat mass, insulin resistance, or haemoglobin A1c level. Besides, high plasma visfatin level predicted mortality in patients with CKD after adjustment for age and sex, but not after additional correction for GFR, sVCAM-1, serum albumin and serum IL-6 levels. These authors suggest that circulating levels of visfatin are influenced by renal function but are not associated with fat mass or surrogate markers of insulin resistance in patients with CKD [142] .
More recently, there have been reported novel links between visfatin and anorexia in CKD patients. Elevated circulating visfatin was associated with self-reported appetite loss and decreased circulating levels of amino acids and triglycerides in advanced CKD patients [143] .
In summary, visfatin is able, on one hand, to bind to the insulin receptor and mimic insulin actions, and on the other hand, may induce the expression of IL-6 and other pro-inflammatory cytokines contributing to insulin resistance and vascular damage. Further studies are needed to understand the role of visfatin in the control of appetite in uraemia.
TNF-α. TNF-α is a well-known pro-inflammatory cytokine [144] . It is expressed as a 26-kDa cell surface transmembrane protein that undergoes cleavage to produce a 17-kDa soluble, biologically active form. In humans, TNF-α is expressed and secreted by adipocytes and macrophages in the stromal vascular fraction of the adipose tissue. Adipose tissue TNF-α also acts in an autocrine and paracrine fashion. Although initially suspected of playing a role in cachexia, TNF-α has been implicated in the pathogenesis of obesity and insulin resistance. Adipose tissue TNF-α correlates with BMI, percentage of body fat and hyperinsulinaemia, and weight loss decreases TNF-α levels [145, 146] .
Patients with CKD exhibited high plasma levels of TNF-α [147, 148] , and gene expression of TNF-α in circulating blood cells is enhanced in uraemic patients [149] . An increased mortality in HD patients with elevated serum concentrations of TNF-α together with other pro-inflammatory cytokines (IL-1 and IL-6) has been reported. It might be related to increased risk for cardiovascular mortality [150] . In a study performed in PD patients, subjects with anorexia or anorexia with nausea or vomiting had higher TNF-α values than patients without these symptoms [151] . Patients with prior diagnosis of acid pylori disease also showed higher TNF-α values in comparison with unaffected patients. Furthermore, TNF-α values were inversely associated with transferring, cholesterol, blood urea nitrogen and prealbumin. In summary, in PD patients, high TNF-α levels have been associated with anorexia and a poor nutritional status.
Interleukin-6. IL-6 is a pro-inflammatory cytokine similar to TNF-α that is not exclusively expressed in adipose tissue, although it is estimated that ∼25% of systemic IL-6 is secreted by subcutaneous fat cells [152] . Visceral fat has a greater capacity to produce IL-6 in comparison with subcutaneous fat in vitro [153] . IL-6 circulates in multiple glycosylated forms ranging from 22 to 27 kDa and is a 2072 Nephrol Dial Transplant (2010): Editorial Reviews pleiotropic circulating cytokine with multiple effects ranging from inflammation to host defence and tissue injury. Some epidemiological studies have suggested that plasma IL-6 concentrations correlate positively with human obesity and insulin resistance, and high IL-6 levels are predictive of type 2 diabetes [154] . IL-6 has been proposed to affect glucose homeostasis and metabolism directly and indirectly by action on skeletal muscle cells, adipocytes, hepatocytes, pancreatic beta-cells and neuroendocrine cells. IL-6 action contributes to, but is probably neither necessary nor sufficient for, the development of diabetes [155] .
Several investigations have been reported showing that IL-6 serum concentrations are reliable predictors of mortality in patients with end-stage renal disease [156] [157] [158] [159] [160] . A recent survey, including a group of 120 HD patients, has shown that mortality was significantly higher in patients with IL-6 above the median value and also in subjects with TNF-α above the median values, with hazard ratio values of 6.38 and 4.56, respectively, thus suggesting that IL-6 is a better predictor of mortality than TNF-α in HD population [161] . A better predictor value for IL-6 in comparison with TNF-α has been confirmed in another survey of 125 patients with CKD at stages 2-5 [162] .
Resistin. Resistin has been identified as a novel adiposespecific cysteine-rich protein. It is a 12.5-kDa polypeptide [163] . This adipokine has been involved in the regulation of metabolism, inhibition of adipogenesis and inflammation [164] . Resistin levels have been shown to be increased in patients with moderate renal failure, and this increase has been inversely related to glomerular filtration rate [165] . Dialysis (HD and PD) patients exhibit similar resistin levels, and these levels are almost two times higher than those found in patients on conservative therapy [110] . A significant relationship between resistin and heart disease in dialysis patients has been reported [110] .
Conclusion
In summary, many aspects of the pathophysiology of adipose tissue in patients with CKD are challenging and are not well understood at present. Although our methods of measuring fat mass have significantly improved in recent years, there is no simple, precise and cost-effective method of measurement that can be implemented in clinical practice. There are also conflicting epidemiological data regarding the relationship between fat mass and risk of cardiovascular disease and death. The most reliable data suggest a strong relationship between malnutrition and mortality, but the 'obesity paradox' raises the worrisome question of whether the relationships between excess fat mass and mortality are different in the general population and in patients with CKD. Moreover, an intense research has been developed in recent years on the pathophysiology of adipokines in renal disease and on the relationship between these adipose tissue-derived proteins and the risk of cardiovascular disease in uraemic patients. The direct association between some pro-inflammatory cytokines and cardiovascular morbidity and mortality seems clear, but doubt persists on the pathophysiological role and potential implications of other adipokines, such as adiponectin. Further investigations on the relationship between adipose tissue and its secretory products with the various pathophysiological aspects of renal disease are warranted. 
Introduction
Many patients with heart failure have underlying renal dysfunction, and similarly, patients with kidney failure are prone to cardiac failure. This has led to the concept of cardio-renal syndromes, which can be an acute or chronic cardio-renal syndrome, when cardiac failure causes deterioration in renal function, or acute and/or chronic Reno-Cardiac syndrome, when renal dysfunction leads to cardiac failure. Patients who develop these syndromes have increased risk of hospital admission and mortality. Although there are clinical guidelines for managing both heart failure and chronic kidney disease, there are no agreed guidelines for managing patients with cardio-renal and/or Reno-Cardiac syndromes, as these patients have typically been excluded from clinical trials. We have therefore reviewed the currently available published literature to outline a consensus of current best clinical practice for these patients.
